INAB IN8BIO, INC.
Nasdaq · SEC CIK 1740279 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 168 since 2021-08-02, latest 2026-05-29 17:39
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Rochlin Kate | COO | — | — |
| McCall Patrick | CFO | — | — |
| Ho William Tai-Wei | Pres AND CEO, Dir, 10% | — | — |
| FAIRBAIRN EMILY | Dir | — | — |
| Roemer Alan S. | Dir | — | — |
| Brandt Peter C. | Dir | — | — |
Transactions 54
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2026-05-29 17:39 | 2026-05-27 | INAB | FAIRBAIRN EMILY | Dir | G - Gift | $0.00 | -724.6K | 0 | -100% | $0 |
| 2025-12-23 | 2025-12-22 | INAB | Roemer Alan S. | Dir | A - Grant | $1.38 | +36.2K | 49.5K | +273% | +$50.0K | |
| 2025-12-23 | 2025-12-22 | INAB | Rochlin Kate | COO | A - Grant | $1.38 | +7,247 | 9,085 | +394% | +$10.0K | |
| I | 2025-12-23 | 2025-12-22 | INAB | FAIRBAIRN EMILY | Dir | A - Grant | $1.38 | +724.6K | 724.6K | New | +$1000.0K |
| 2025-12-23 | 2025-12-22 | INAB | Ho William Tai-Wei | Pres AND CEO, Dir, 10% | A - Grant | $1.38 | +36.2K | 121.2K | +43% | +$50.0K | |
| 2025-12-23 | 2025-12-22 | INAB | McCall Patrick | CFO | A - Grant | $1.38 | +7,247 | 9,482 | +324% | +$10.0K | |
| 2025-12-23 | 2025-12-22 | INAB | Brandt Peter C. | Dir | A - Grant | $1.38 | +72.5K | 95.2K | +319% | +$100.0K | |
| DM | 2025-05-07 | 2025-04-30 | INAB | Roemer Alan S. | Dir | M - OptEx | $0.18 | +113.5K | 387.5K | +41% | +$20.4K |
| D | 2025-05-07 | 2025-04-30 | INAB | Rochlin Kate | COO | M - OptEx | $0.18 | +12.3K | 55.2K | +29% | +$2,213 |
| D | 2025-05-07 | 2025-04-30 | INAB | McCall Patrick | CFO | M - OptEx | $0.18 | +15.0K | 67.1K | +29% | +$2,700 |
| DM | 2025-05-07 | 2025-04-30 | INAB | Brandt Peter C. | Dir | M - OptEx | $0.18 | +163.9K | 681.5K | +32% | +$29.5K |
| D | 2024-10-08 | 2024-10-04 | INAB | Ho William Tai-Wei | Pres AND CEO, Dir, 10% | A - Grant | — | +126.6K | 2.55M | +5% | — |
| D | 2024-10-08 | 2024-10-04 | INAB | Brandt Peter C. | Dir | A - Grant | — | +253.2K | 517.6K | +96% | — |
| D | 2024-10-08 | 2024-10-04 | INAB | Rochlin Kate | COO | A - Grant | — | +25.3K | 42.9K | +144% | — |
| D | 2024-10-08 | 2024-10-04 | INAB | Roemer Alan S. | Dir | A - Grant | — | +126.6K | 285.0K | +80% | — |
| D | 2024-10-08 | 2024-10-04 | INAB | McCall Patrick | CFO | A - Grant | — | +25.3K | 52.1K | +95% | — |
| D | 2023-12-15 | 2023-12-13 | INAB | McCall Patrick | CFO | A - Grant | — | +20.5K | 26.8K | +327% | — |
| D | 2023-12-15 | 2023-12-13 | INAB | Graff Jeremy R. | Dir | A - Grant | — | +2,049 | 4,549 | +82% | — |
| D | 2023-12-15 | 2023-12-13 | INAB | Epperly Corinne | Dir | A - Grant | — | +82.0K | 82.0K | New | — |
| D | 2023-12-15 | 2023-12-13 | INAB | Roemer Alan S. | Dir | A - Grant | — | +102.5K | 158.4K | +183% | — |
| D | 2023-12-15 | 2023-12-13 | INAB | Rochlin Kate | COO | A - Grant | — | +12.3K | 17.6K | +234% | — |
| D | 2023-12-15 | 2023-12-13 | INAB | Brandt Peter C. | Dir | A - Grant | — | +82.0K | 264.4K | +45% | — |
| D | 2023-12-15 | 2023-12-13 | INAB | Goswami Trishna | Chief Medical Off | A - Grant | — | +4,098 | 6,729 | +156% | — |
| D | 2023-12-15 | 2023-12-13 | INAB | Lamb Lawrence | EVP, CSO | A - Grant | — | +1,639 | 101.4K | +2% | — |
| D | 2023-12-15 | 2023-12-13 | INAB | Ho William Tai-Wei | Pres, CEO, Dir, 10% | A - Grant | — | +82.0K | 2.42M | +4% | — |
| 2023-09-15 | 2023-09-13 | INAB | Graff Jeremy R. | Dir | P - Purchase | $0.95 | +2,500 | 2,500 | New | +$2,375 | |
| 2023-08-28 | 2023-08-25 | INAB | McCall Patrick | CFO | P - Purchase | $1.03 | +1,000 | 6,263 | +19% | +$1,030 | |
| 2023-08-28 | 2023-08-24 | INAB | Ho William Tai-Wei | Pres, CEO, Dir, 10% | P - Purchase | $1.05 | +23.8K | 2.34M | +1% | +$25.0K | |
| I | 2023-08-01 | 2023-07-28 | INAB | FAIRBAIRN EMILY | Dir | J - Other | $0.00 | -4.11M | 0 | -100% | $0 |
| MI | 2022-12-13 | 2022-12-12 | INAB | BIOS Fund III QP, LP | Dir, 10% | P - Purchase | $2.48 | +75.0K | 570.7K | +15% | +$186.0K |
| MI | 2022-12-13 | 2022-12-12 | INAB | Kreis Leslie W. | Dir, 10% | P - Purchase | $2.48 | +75.0K | 570.7K | +15% | +$186.0K |
| MI | 2022-09-29 | 2022-09-28 | INAB | Bios Equity Partners II, LP | Dir, 10% | P - Purchase | $2.02 | +25.0K | 562.0K | +5% | +$50.5K |
| MI | 2022-09-29 | 2022-09-28 | INAB | BIOS Fund II NT, LP | Dir, 10% | P - Purchase | $2.02 | +25.0K | 562.0K | +5% | +$50.5K |
| MI | 2022-08-30 | 2022-08-26+ | INAB | BIOS Fund II QP, LP | Dir, 10% | P - Purchase | $2.02 | +51.2K | 559.1K | +10% | +$103.3K |
| MI | 2022-08-30 | 2022-08-26+ | INAB | Cavu Advisors, LLC | Dir, 10% | P - Purchase | $2.02 | +51.2K | 559.1K | +10% | +$103.3K |
| 2022-08-18 | 2022-08-16 | INAB | Goswami Trishna | Chief Medical Off | P - Purchase | $1.90 | +2,631 | 2,631 | New | +$4,999 | |
| MI | 2022-08-18 | 2022-08-17 | INAB | BIOS Fund II NT, LP | Dir, 10% | P - Purchase | $1.93 | +50.0K | 553.1K | +10% | +$96.5K |
| 2022-08-18 | 2022-08-16 | INAB | Ho William Tai-Wei | Pres, CEO, CFO, Dir | P - Purchase | $1.90 | +26.3K | 2.32M | +1% | +$50.0K | |
| 2022-08-18 | 2022-08-16 | INAB | Roemer Alan S. | Dir | P - Purchase | $1.90 | +26.3K | 56.0K | +89% | +$50.0K | |
| 2022-08-18 | 2022-08-16 | INAB | McCall Patrick | CFO | P - Purchase | $1.90 | +5,263 | 5,263 | New | +$10,000 | |
| 2022-08-18 | 2022-08-16 | INAB | Greenwood Luba | Dir | P - Purchase | $1.90 | +526 | 7,826 | +7% | +$999.40 | |
| 2022-08-18 | 2022-08-16 | INAB | Brandt Peter C. | Dir | P - Purchase | $1.90 | +105.3K | 182.5K | +136% | +$200.0K | |
| 2022-08-18 | 2022-08-16 | INAB | Rochlin Kate | COO | P - Purchase | $1.90 | +5,263 | 5,263 | New | +$10,000 | |
| 2022-08-18 | 2022-08-16 | INAB | Lamb Lawrence | EVP, CSO | P - Purchase | $1.90 | +526 | 99.7K | +0.5% | +$999.40 | |
| MI | 2022-08-18 | 2022-08-17 | INAB | Cavu Management, LP | Dir, 10% | P - Purchase | $1.93 | +50.0K | 3.61M | +1% | +$96.5K |
| I | 2022-08-18 | 2022-08-16 | INAB | Transcend Partners Opportunity Fund LLC | 10% | P - Purchase | $1.90 | +789.5K | 4.11M | +24% | +$1.50M |
| MI | 2022-08-17 | 2022-08-16 | INAB | BIOS Advisors GP, LLC | Dir, 10% | P - Purchase | $1.90 | +1.77M | 540.3K | New | +$3.37M |
| MI | 2022-08-17 | 2022-08-16 | INAB | BIOS Fund II, LP | Dir, 10% | P - Purchase | $1.90 | +1.77M | 540.3K | New | +$3.37M |
| D | 2022-05-09 | 2022-05-05 | INAB | Lamb Lawrence | EVP, CSO | M - OptEx | $1.07 | +26.2K | 99.2K | +36% | +$28.0K |
| DI | 2021-08-03 | 2021-08-03 | INAB | Transcend Partners Opportunity Fund LLC | 10% | P - Purchase | $10.00 | +100.0K | 3.32M | +3% | +$1.00M |
| DMI | 2021-08-03 | 2021-08-03 | INAB | Transcend Partners Opportunity Fund LLC | 10% | C - Cnv Deriv | — | +3.33M | 27.7K | New | — |
| DMI | 2021-08-03 | 2021-08-03 | INAB | BIOS Capital Management, LP | 10% | C - Cnv Deriv | — | +6.63M | 359.4K | New | — |
| DI | 2021-08-03 | 2021-08-03 | INAB | Ho William Tai-Wei | Pres, CEO, CFO, Dir | C - Cnv Deriv | — | +3,070 | 73.0K | +4% | — |
| DMI | 2021-08-03 | 2021-08-03 | INAB | BIOS Fund II NT, LP | 10% | C - Cnv Deriv | — | +6.63M | 1.88M | New | — |
Purchase Sale Sale after option exercise All abbreviations